Close Menu

NEW YORK (GenomeWeb) – Biocept announced today it has priced a public offering expected to raise approximately $10 million in gross proceeds.

Biocept is offering 9.1 million shares of its common stock, as well as warrants to purchase up to an aggregate of 9.1 million shares at a combined offering price of $1.10 per share. The warrants are exercisable immediately and will expire five years from the date of issuance, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.